217 related articles for article (PubMed ID: 28228122)
21. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
22. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
23. High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study.
Bang SM; Cho EK; Suh C; Yoon SS; Seong CM; Cho KS; Kang YG; Park S; Ahn MJ; Park YS; Oh D; Kim HC; Jung CW; Kim S; Lee JH
J Korean Med Sci; 2003 Oct; 18(5):673-8. PubMed ID: 14555819
[TBL] [Abstract][Full Text] [Related]
24. Pilot Trial of Homebound Hematopoietic Cell Transplantation.
Landau HJ; Orlando E; Rodriguez ES; Applebaum A; Mitchell HR; Peled JU; Khan N; Funnell T; Chung D; Scordo M; Shah GL; LeStrange NJ; Hambright KA; McElrath CM; Cazeau N; Devlin SM; Perales MA; Giralt SA
Transplant Cell Ther; 2022 Dec; 28(12):832.e1-832.e7. PubMed ID: 36182105
[TBL] [Abstract][Full Text] [Related]
25. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Child JA; Morgan GJ; Davies FE; Owen RG; Bell SE; Hawkins K; Brown J; Drayson MT; Selby PJ;
N Engl J Med; 2003 May; 348(19):1875-83. PubMed ID: 12736280
[TBL] [Abstract][Full Text] [Related]
26. Serum metabolomic profiling correlated with ISS and clinical outcome for multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation.
Veskovski L; Andersson PO; Turesson I; Malmodin D; Pedersen A; Mellqvist UH
Exp Hematol; 2021 May; 97():79-88.e8. PubMed ID: 33609593
[TBL] [Abstract][Full Text] [Related]
27. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
[TBL] [Abstract][Full Text] [Related]
28. Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma.
Wichert S; Pettersson Å; Hellmark T; Johansson Å; Hansson M
Exp Hematol; 2016 May; 44(5):342-351.e5. PubMed ID: 26774385
[TBL] [Abstract][Full Text] [Related]
29. Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients.
Powles R; Sirohi B; Kulkarni S; Bhagwati N; Saso R; Raje N; Horton C; Singhal S; Mehta J; Treleaven J
Bone Marrow Transplant; 2000 May; 25(9):949-56. PubMed ID: 10800062
[TBL] [Abstract][Full Text] [Related]
30. Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis.
Hillengass J; Ho AD; Goldschmidt H; Waldherr R; Moehler TM
Int J Hematol; 2008 Nov; 88(4):454-456. PubMed ID: 18846323
[TBL] [Abstract][Full Text] [Related]
31. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
32. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
Voorhees PM; Usmani SZ
Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290
[TBL] [Abstract][Full Text] [Related]
33. Treatment of myeloma: recent developments.
Zweegman S; Huijgens PC
Anticancer Drugs; 2002 Apr; 13(4):339-51. PubMed ID: 11984079
[TBL] [Abstract][Full Text] [Related]
34. [High-dose melphalan with stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective].
Hjorth M; Lenhoff S; Turesson I; Westin J
Lakartidningen; 2000 Oct; 97(41):4585-6, 4589-92. PubMed ID: 11107744
[TBL] [Abstract][Full Text] [Related]
35. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
[TBL] [Abstract][Full Text] [Related]
36. Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma.
Weaver CH; Zhen B; Schwartzberg LS; Leff R; Magee M; Geier L; Deaton K; Lewkow L; Buckner CD
Bone Marrow Transplant; 1998 Aug; 22(3):245-51. PubMed ID: 9720737
[TBL] [Abstract][Full Text] [Related]
37. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
38. [Value of hematopoietic stem cell autotransplantation in the treatment of multiple myeloma: initial experience at the National Bone Marrow Transplantation Center and review of the literature].
Abdelkefi A; Ladeb S; Ben Othman T; Torjman L; Jeddi R; Ben Abdeladhim A
Tunis Med; 2000 Oct; 78(10):548-56. PubMed ID: 11190737
[TBL] [Abstract][Full Text] [Related]
39. Multiple myeloma.
Holstein SA; Liu H; McCarthy PL
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1113-29. PubMed ID: 25459182
[TBL] [Abstract][Full Text] [Related]
40. Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.
Gebauer N; Biersack H; Czerwinska AC; Schemme J; Hardel TT; Bernard V; Rades D; Lehnert H; Luley KB; Thorns C
Leuk Lymphoma; 2016; 57(1):226-9. PubMed ID: 25947035
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]